SCHEMBL5365741

SCHEMBL5365741

COC(=O)c1cc(Cl)ccc1Oc1ccc(Cl)cn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.50
GRM8 O00222 1/20 0.48
GRM7 Q14831 1/20 0.48
GRM4 Q14833 1/20 0.48
ALDH1A1 P00352 2/20 0.44
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
S1PR4 O95977 1/20 0.43
USP2 O75604 1/20 0.43
PABPC1 P11940 1/20 0.43
MRGPRX4 Q96LA9 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
NR4A2 P43354 2/20 0.42
LMNA P02545 1/20 0.42
NPC1 O15118 1/20 0.41
TP53 P04637 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5367633 0.90 P2RX3 (0.48) ABL1ALDH1A1MEN1KMT2AUSP2
SCHEMBL25256743 0.90 MEN1 (0.49) ABL1GRM8GRM7GRM4ALDH1A1
SCHEMBL5357758 0.90 ABL1 (0.49) ABL1GRM8GRM7GRM4ALDH1A1
SCHEMBL30488795 0.90 MEN1 (0.49) ABL1GRM8GRM7GRM4ALDH1A1
SCHEMBL5373256 0.85 PABPC1 (0.57) ALDH1A1MEN1KMT2APABPC1SMN1; SMN2
SCHEMBL22208638 0.85 MAPK10 (0.46) ABL1TDP1LMNAL3MBTL1
SCHEMBL31697202 0.85 MAPK10 (0.46) ABL1TDP1LMNAL3MBTL1
SCHEMBL5363242 0.84 GAA (0.51) GRM8GRM7GRM4ALDH1A1MEN1
SCHEMBL25250610 0.83 ABL1 (0.37) ABL1GRM8GRM7GRM4ALDH1A1
SCHEMBL25300716 0.80 PTGDR2 (0.37) ABL1MEN1KMT2AS1PR4USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1663979-B1 PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS RAQUALIA PHARMA INC (JP) 2013-10-09 EP disclosed
US-7238714-B2 Aryl or heteroaryl amide compounds PFIZER JAPAN, INC. (JP) 2007-07-03 US disclosed
EP-1663979-A1 PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS PFIZER INC. (US) 2006-06-07 EP disclosed
US-20050065188-A1 Aryl or heteroaryl amide compounds ASKAT INC. (JP) 2005-03-24 US disclosed
WO-2005021508-A1 PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS PFIZER INC. (US) 2005-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065188-A1 Aryl or heteroaryl amide compounds HRH2, PTGER1, LTB4R2 ABL1 1117/4885GRM8 1852/4885GRM7 2056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.